24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Gamida Cell
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
22:27
Five months old, Noetive raises $41 million Seed to build AI for the physical economy
20:39
The man who helped build Palo Alto’s Cortex is leaving the company
20:20
Wiz founders Rappaport and Costica add television to their post-exit portfolio with $120 million Reshet 13 deal
17:12
Israel’s tech exports hit a record but foreign owners are claiming more of the gains
More stories
Buzz
Most popular
Daily
Weekly
1
How an Israeli engineer went from Rafael to iPhone Portrait Mode and a $300 million OpenAI exit
2
Oracle is expanding layoffs but its new CFO says “don’t do more with less”
3
The ThinkPad X13 is almost boring, and that’s exactly the point
4
Buildots raises $130 million at nearly $1 billion valuation as AI boom drives data center construction
5
Former Mossad chief Yossi Cohen joins Israeli quantum tech company Quantum X Labs
More news
Gamida Cell
5 stories about Gamida Cell
Gamida Cell announces $75 million financing with Highbridge Capital Management
16.02.21
|
CTech
The Israeli company is developing and commercializing cures for blood cancers and serious hematologic diseases
Gamida Cell Downprices Shares to Raise $50 Million Nasdaq IPO
28.10.18
|
Lilach Baumer
The Israel-based biotech company offered its shares at $8, below its previous intention of $13 to $15 per share
Novartis-Backed Gamida Downgrades Nasdaq IPO Expectations to $50-$60 Million
18.10.18
|
Lilach Baumer
The Jerusalem-based biotech company filed for a $69 million initial public offering in September but disclosed no pricing terms
Biotech Company Gamida Cell Files for $69 Million Nasdaq IPO
30.09.18
|
Dror Reich
The Jerusalem-based company develops cellular and immune therapies. Its lead product is a universal bone marrow transplant solution
Pharma Veteran Julian Adams takes Helm at Gamida Cell
21.11.17
|
Lilach Baumer
The Novartis-backed company is developing a universal bone marrow transplant solution for patients unable to find a donor